England is the first country in the world to make GSK's anti-BCMA drug Blenrep available to patients with the haematological ...

Sundar Jagannath, MBBS, highlights long-term follow-up data from the phase 1b/2 CARTITUDE-1 trial, showing durable responses and potential cures with ciltacabtagene autoleucel in patients with ...

The NHS in England will be the first health system in the world to roll-out a ‘trojan horse’ targeted therapy for blood cancer patients which could halt the disease’s progression by nearly three times ...

Alfred L. Garfall, MD, provided a deep dive into the phase 2 BMT CTN 1902 trial of ide-cel in multiple myeloma after ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as ...

A “Trojan horse” therapy that sneaks toxic drugs inside cancer cells is being made available on the NHS in England in a world ...

England's blood cancer patients are the first globally to receive a revolutionary 'Trojan horse' drug, belantamab mafodotin, ...

A meta-analysis suggests allogeneic stem cell transplantation (allo-SCT) should not be recommended following first-line ...

Terminal patients could get years more with their loved ones as the NHS offers Blenrep, which can put some blood cancer ...

Renal failure in multiple myeloma typically occurs when the kidneys fail to filter waste products from the blood, leading to ...

It has been dubbed a “Trojan horse” treatment because it works by being taken into a cancer cell, before releasing a high ...